Enzyme-Linked Immunosorbent Assay (ELISA)
Therapeutic drug monitoring.
USTEKINUMAB QN, S: Limit of quantitation is 0.3 mcg/mL
In inflammatory bowel disease, at post-induction measurement (week 8), concentrations above 3.5 mcg/mL are associated with good outcomes
For maintenance stages:
Concentrations > or =1.0 mcg/mL are associated with clinical response and clinical remission
Concentrations > or =4.5 mcg/mL are associated with mucosal healing
USTEKINUMAB AB, S: Limit of quantitation is 10 AU/mL
Absent: <10 AU/mL
Present: > or =10 AU/mL
* Reference ranges may change over time. Please refer to the original patient report when evaluating results.
3 - 7 days
Collect trough specimen in Red or SST tube. Spin and aliquot serum into a screw capped plastic tube. Send to Specimen Processing refrigerated
Collect trough specimen in an Red or SST tube.
Test sent to Mayo Clinic Laboratories